Abbvie (ABBV) PT Raised to $181 at Morgan Stanley
Get Alerts ABBV Hot Sheet
Price: $257.49 -1.05%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
Morgan Stanley analyst Terrance Flynn raised the price target on Abbvie (NYSE: ABBV) to $181.00 (from $178.00) while maintaining a Overweight rating.
You May Also Be Interested In
- AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- Asana (ASAN) PT Raised to $10 at UBS, Neutral Rating Maintained on 'Full' Valuation
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share